Development of a vaccine against avian reovirus infection in broiler chickens

肉鸡禽呼肠孤病毒感染疫苗的研制

• 批准号: 523836-2018
• 负责人: Gomis, Susantha
• 金额: $ 5.83万
• 依托单位: University of Saskatchewan
• 依托单位国家: 加拿大
• 项目类别: Collaborative Research and Development Grants
• 财政年份: 2020
• 资助国家: 加拿大
• 起止时间: 2020-01-01 至 2021-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=697690
• 关键词: Development; vaccine; against; avian; reovirus

Avian reoviruses (ARVs) are etiological agents for an economically important emerging poultry disease. Arthrogenic ARVs cause tenosynovitis/arthritis syndrome which is characterized by unilateral or bilateral swelling of the hock joint resulting in lameness. Depending on the severity, ARV infection results in poor growth and poor production, and sometimes death, causing considerable economic losses to the poultry industry. While commercial vaccines are available, the incidence of emerging virulent strains of ARV that continue to impact the Canadian poultry industry suggest that current vaccines are not effective against circulating ARV strains. Vaccination is the preferred means to protect broiler chickens from ARV infection. Currently, some farms in Canada use autogenous vaccines to prevent ARV infection in chickens; however, autogenous vaccines induce unpredictable immunity and have limited potential as a dedicated control measure against ARVs. There is no effective vaccine available against the emerging ARV strains currently circulating in the Canadian broiler chicken industry. If ARVs continue to cause disease, the Canadian broiler chicken industry will continue to suffer significant economic losses. Therefore, the development of a safe and an effective vaccine based on the characteristics of circulating virulent strains of ARV is essential. We have characterized emerging variant ARVs from the broiler chicken industry in Saskatchewan at the genetic and immunological level. We have demonstrated that four genotypes of ARV affect the Saskatchewan broiler chicken industry and these genotypes cannot be controlled by a ARV vaccine containing just one type. We propose to develop a safe and effective multivalent live and inactivated vaccine against ARVs specifically tailored for the Canadian poultry industry to control emerging ARV infections.

禽呼肠孤病毒(ARV)是一种新出现的经济上重要的禽病的病原体。 关节源性抗逆转录病毒药物可引起以单侧或双侧为特征的腱鞘炎/关节炎综合征 飞节肿胀，导致跛行。根据严重程度的不同，ARV感染会导致 生长和产量低下，有时甚至死亡，给家禽造成相当大的经济损失 工业。虽然有商业疫苗可用，但出现的ARV强毒株的发病率 继续影响加拿大家禽业表明目前的疫苗对 循环中的ARV毒株。接种疫苗是保护肉鸡免受ARV感染的首选手段。 目前，加拿大一些养殖场使用自体疫苗来预防鸡只感染ARV；然而， 自体疫苗导致不可预测的免疫，作为一种专门的控制措施的潜力有限 对抗抗逆转录病毒药物。目前还没有针对目前在中国流行的新出现的ARV毒株的有效疫苗 加拿大的肉鸡产业。如果抗逆转录病毒继续导致疾病，加拿大肉鸡 工业将继续遭受重大的经济损失。因此，开发一种安全可靠的 基于ARV流行强毒株特性的有效疫苗至关重要。我们有 描述了萨斯喀彻温省肉鸡业新出现的变种抗逆转录病毒基因和 免疫学水平。我们已经证明了四种ARV基因类型会影响萨斯喀彻温省的肉鸡 这些基因型别不能由只含有一种型别的ARV疫苗控制。我们 建议开发安全有效的抗逆转录病毒多价活疫苗和灭活疫苗 为加拿大家禽业量身定做，以控制新出现的ARV感染。